Clinical and pathological features and prognosis of breast cancer patients with HER2 low expression and HER2 negative expression
Objective To analyze the clinical and pathological features and prognosis of breast cancer patients with human epidermal growth factor receptor 2(HER2)low expression and HER2 negative expression.Methods A total of 257 breast cancer patients without HER2-overexpression underwent surgical resection,of whom 82 cases were with luminal type A breast cancer,118 cases were with luminal type B breast cancer,and 57 cases were with triple-negative type breast cancer.The clinical and pathological features and prognosis of HER2 low expression and HER2 negative expression in the patients with non HER2-overexpression,luminal A and B type breast cancer,and triple-negative type breast cancer were analyzed.Results There were significant differences in the proportion of patients of different age,menopausal status,histological grade,percentage of tumor infiltrating lymphocytes(TILs),expressions of programmed death ligand 1(PD-L1)and Ki-67 between the patients with HER2 low expression and those with HER2 negative expression in breast cancer patients without HER2-overexpression(P<0.05 or P<0.01).There were significant differences in the proportion of patients of different age,menopausal status,TILs percentage,PD-L1 expression and Ki-67 expression between the patients with HER2 low expression and HER2 negative expression in breast cancer patients with luminal A and B type breast cancer(P<0.05 or P<0.01).There were significant differences in the proportion of patients of different histological grade,TILs percentage,PD-L1 expression and Ki-67 expression between the patients with HER2 low expression and those with HER2 negative expression in breast cancer patients with triple-negative type breast cancer(P<0.05 or P<0.01).The rates of overall survival(OS)and disease-free survival(DFS)of the patients with HER2 low expression and those with HER2 negative expression in breast cancer patients without HER2-overexpression,or with luminal A and B type were similar(P>0.05).The rates of OS and DFS of the patients with HER2 low expression were higher than those with HER2 negative expression in breast cancer patients with triple-negative type(P<0.05).Conclusion Breast cancer patients with HER2 low expression and HER2 negative expression have different clinical and pathological features and prognosis,and different clinical treatment strategies should be taken according to different HER2 status.
Human epidermal growth factor receptor 2Breast cancer